Press and News
Industry Features
Press and News
Elucidata, a leader in data-centric Al for drug discovery and translational research, and Sapien Biosciences, India's first and largest commercial biobank with 300,000+ patient samples founded in partnership with Apollo Hospitals, today announced a strategic partnership to convert Sapien's extensive biobank assets into Al-ready, multimodal data products for use in drug and diagnostic development.
%201%20(1).svg){kind=icon}
Elucidata ranks 7th globally in Broad Institute’s ML Challenge, advancing AI in histopathology and autoimmune disease research.
Elucidata, the leading data-centric AI solutions and technology company, is proud to welcome Dr. Werner Lanthaler and Dr. Navjot Singh to its leadership team as Independent Board Member and Advisor, respectively.
Elucidata has achieved a remarkable milestone by being named the "Most Innovative Company in the Biotech Category" by Fast Company's Most Innovative Companies in 2024 list.
Biotech firm Elucidata, backed by the likes of IvyCap Ventures and Hyperlane Venture, on Tuesday said it has raised $16 million in a series A round led by global investment firm, Eight Roads Ventures.
.svg)
Big data-driven software platform reduces the time from experiment design to discovery through analysis and visualization of -omics drug discovery data.
BOSTON, Mass., Nov. 21, 2022 -- /PRNewswire/ – TetraScience, the Scientific Data Cloud company, announced today that Elucidata, whose data-centric platform Polly powers biological discovery with ML-ready biomedical data
From young startups to major conglomerates, almost every organization in the life sciences industry is looking at AI to drive R&D and come up with and therapies.
.svg){kind=logo}
CAMBRIDGE, Mass., Sept. 27, 2022 /PRNewswire/ -- Elucidata, a TechBio company that powers life science research & development (R&D) with its data-centric Machine Learning Operations (ML-Ops) platform, Polly,
.svg)
Elucidata, a Cambridge, MA-based TechBio company that powers life science research and development (R&D) with its data-centric Machine Learning Operations (ML-Ops) platform, Polly, announced that it raised $16 million in Series A funding.
The round was led by Eight Roads Ventures, with participation from F-Prime Capital, IvyCap Ventures, and Hyperplane Venture Capital
The funds raised will be used by Elucidata’s data-centric Machine Learning Operations (ML-Ops) platform, Polly to deepen product capabilities in translational drug research and allied markets,
Elucidata, the data science start-up focused on making better drugs, faster, has announced its plans to double its workforce by 2019.
New Delhi [India] June 19 (ANI/NewsVoir): Elucidata, the data science start-up focused on making better drugs, faster, has announced its plan to double its workforce by 2019.
Featured Posts
.svg)
.svg)
.svg)
%201%20(1).svg)
%20(1).svg)
%201%20(1).svg)
.svg)
%201.svg){kind=icon}
